TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma.
Our purpose was to determine if fine-needle aspirates of pancreatic adenocarcinoma would produce material amenable to tumor marker staining and to correlate the expression of TGF-beta and p53 with patient and tumor data. One hundred twenty specimens were analyzed. TGF-beta was positive in 26% of cases and had no correlation with patient's age, sex, survival, stage, grade, or size. p53 was positive in 22% of the cases and correlated only with grade 1 tumors. Expression of TGF-beta and p53 can be tested on preserved cytologic specimens. This is the largest study to date correlating TGF-beta and p53 expression in pancreatic adenocarcinoma and patient demographics, prognosis, and tumor attributes. This is also the first study that did not select for surgical candidates. TGF-beta expression does not appear to have prognostic significance in pancreatic cancer. p53 was more common in well-differentiated tumors and may be an early mutation lost in more poorly differentiated tumors.
Sears
Dawn
D
Department of Medicine and Gastroenterology, Scott & White Memorial Hospital, Temple, Texas 76502, USA. dsears@swmail.sw.org
Erickson
Richard A
RA
Sayage-Rabie
Lubna
L
Escobar
Martha C
MC
D000230:Adenocarcinoma / Q000473:pathology*; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D044963:Biopsy, Fine-Needle / Q000379:methods; D019160:Endosonography / Q000379:methods; D005260:Female; D006801:Humans; D008233:Lymphotoxin-alpha / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000473:pathology*; D011379:Prognosis; D013194:Staining and Labeling; D014057:Tomography, X-Ray Computed / Q000379:methods; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D014408:Biomarkers, Tumor; D008233:Lymphotoxin-alpha; D016159:Tumor Suppressor Protein p53